Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

[Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].

Yang H, Zhu HY, Jiang MM, Wang QS, Han XP, Huang WR, Jing Y, Wang SH, Zhang SS, Mei JH, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):121-5. doi: 10.7534/j.issn.1009-2137.2013.01.025. Chinese.

PMID:
23484704
2.

Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.

Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.

Asian Pac J Cancer Prev. 2015;16(15):6627-32.

3.

[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].

Yang XL, Wu YM, Cao YB, Li XH, Xu LX, Liu ZY, Liu B, Yan B, Li SW, DA WM, Wu XX.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Aug;23(4):1056-61. doi: 10.7534/j.issn.1009-2137.2015.04.030. Chinese.

PMID:
26314446
4.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320
5.

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM.

Cancer. 2015 Feb 15;121(4):556-61. doi: 10.1002/cncr.29085. Epub 2014 Oct 21.

6.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. doi: 10.1016/j.bbmt.2015.05.026. Epub 2015 Jun 5.

7.

[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].

Gao S, Qiu H, Jin Z, Tang X, Fu Z, Ma X, Han Y, Chen S, Sun A, Wu D.

Zhonghua Xue Ye Xue Za Zhi. 2014 Nov;35(11):961-5. doi: 10.3760/cma.j.issn.0253-2727.2014.11.001. Chinese.

PMID:
25417868
8.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
9.

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.

Wu D, Du X, Jin J, Xiao Z, Shen Z, Shao Z, Li X, Huang X, Liu T, Yu L, Li J, Chen B, He G, Cai Z, Liang H, Li J, Ruan C.

Adv Ther. 2015 Nov;32(11):1140-59. doi: 10.1007/s12325-015-0263-8. Epub 2015 Nov 14.

10.

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.

Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY, He Q, Zhang QX, Li X.

Ann Hematol. 2012 Dec;91(12):1879-86. doi: 10.1007/s00277-012-1550-y. Epub 2012 Aug 16.

PMID:
22895556
11.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G.

Leukemia. 2016 Feb;30(2):268-73. doi: 10.1038/leu.2015.244. Epub 2015 Sep 14.

12.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031
13.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP.

Cancer. 2007 Mar 15;109(6):1133-7.

14.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.

Br J Haematol. 2016 Jan;172(2):238-45. doi: 10.1111/bjh.13829. Epub 2015 Nov 16.

PMID:
26568032
15.

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J.

Cancer Chemother Pharmacol. 2008 Apr;61(5):759-66. Epub 2007 Jun 13.

PMID:
17564707
16.

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.

Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8.

17.

[Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].

Dou LP, Jing Y, Wang QS, Mei JH, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):662-6. doi: 10.7534/j.issn.1009-2137.2013.03.025. Chinese.

PMID:
23815918
18.

[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):459-63. Chinese.

PMID:
19379588
19.

[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].

Zhou J, Wang J, Liu H, Zheng H, Ma L, Wang P, Yan S, Wu D, Fu C, Qiu H, Tang X, Jin Z, Han Y, Miao M.

Zhonghua Yi Xue Za Zhi. 2015 Mar 31;95(12):920-4. Chinese.

PMID:
26081055
20.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113

Supplemental Content

Support Center